Search Results - "Brewer, Jamie Renee"

Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data by Alpert, Ash B, Brewer, Jamie Renee, Adams, Spencer, Rivers, Lexis, Orta, Sunshine, Blosnich, John R, Miedlich, Susanne, Kamen, Charles, Dizon, Don S, Pazdur, Richard, Beaver, Julia A, Fashoyin-Aje, Lola

Get full text

An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC) by Lee, Daniel, Gittleman, Haley, Weinstock, Chana, Suzman, Daniel L., Bloomquist, Erik, Agrawal, Sundeep, Brave, Michael Holman, Brewer, Jamie Renee, Singh, Harpreet, Tang, Shenghui, Pazdur, Richard, Beaver, Julia A., Ibrahim, Amna, Amiri-Kordestani, Laleh

“…Abstract only 4559 Background: The International Metastatic RCC Database Consortium (IMDC) risk model was developed for prognosis of patients with mRCC treated…”
Get full text

Final analysis of a phase II study of MRI based functional imaging of bone metastases in men with metastatic castrate-resistant prostate cancer (mCRPC) receiving cabozantinib by Desai, Arpita, Brewer, Jamie Renee, Medved, Milica, Oto, Aytekin, Gao, Guimin, Karrison, Theodore, Shevrin, Daniel H., Karczmar, Greg S., Stadler, Walter Michael, Szmulewitz, Russell Zelig

“…Abstract only 213 Background: Cabozantinib (C) is a small molecule inhibitor of receptor tyrosine kinases including VEGFR-2, c-MET. C trials have shown…”
Get full text

Association between past medical history (PMH) of autoimmune events and adverse events of special interest (AESI) by Brewer, Jamie Renee, Maher, Virginia Ellen, Weinstock, Chana, Agrawal, Sundeep, Brave, Michael Holman, Ning, Yang-Min, Singh, Harpreet, Suzman, Daniel L., Xu, James, Ibrahim, Amna, Beaver, Julia A., Pazdur, Richard

“…Abstract only 2565 Background: PD-1/L1 inhibitor therapy has become the standard of care for many advanced solid tumors. A notable limitation of PD-1/L1…”
Get full text

Metastasis free survival in older men with nonmetastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: An FDA-pooled analysis by Singh, Harpreet, Zhang, Lijun, Amatya, Anup, Gong, Yutao, Suzman, Daniel L., Weinstock, Chana, Chang, Elaine, Anscher, Mitchell Steven, Chi, Dow-Chung, Xu, James, Brewer, Jamie Renee, Agrawal, Sundeep, Brave, Michael Holman, Hadadi, Mehrnoosh, Theoret, Marc Robert, Kluetz, Paul Gustav, Ibrahim, Amna, Pazdur, Richard, Beaver, Julia A.

“…Abstract only 12038 Background: The FDA has approved three androgen receptor (AR) inhibitors for nonmetastatic castration-resistant prostate cancer (nmCRPC)…”
Get full text